Clinical Trials

Does your developing baby have a heart defect? Have you had a stillborn baby? This study tests a new technology to measure fetal heart activity and find possible problems early. These problems include fetal arrhythmia and conduction disorders such as Brugada syndrome. To participate in this study, you must be at least 18 years old and pregnant, and have one of five high-risk complications of pregnancy: a fetus with a major congenital heart defect, hydrops, or gastroschisis; a previous unexplained stillbirth; or twins who share a placenta. This study is located in Madison and Milwaukee, Wisconsin.

Have you been diagnosed with orthostatic intolerance? This study aims to find out how the body’s regulation of basic functions, such as heart rate and blood pressure, is altered in people who have orthostatic intolerance. This condition, which has an unknown cause, is characterized by a racing heartbeat, dizziness, lightheadedness, and other symptoms that occur when a person stands up. To participate in this study, you must be between 18 and 80 years old and have orthostatic intolerance. This study is located in Nashville, Tennessee.

Do you have heart disease that requires an ICD to prevent sudden cardiac arrest? This study aims to learn what signs distinguish patients who have a higher risk of an arrhythmia that leads to sudden cardiac arrest. Researchers plan to track patients with a recent ICD replacement for 10 years. To participate in this study, you must be between 18 and 85 years old. This study is located in Washington, D.C.; Baltimore, Maryland; and Richmond, Virginia.

Are you an adult with polycythemia vera or thrombocytosis? This study aims to find a new treatment or cure for polycythemia vera and thrombocytosis by locating genes and their changes, or mutations, that may contribute to these disorders. To participate in this study, you must have polycythemia vera with elevated hemoglobin (higher than 18 in men and 16 in women) or thrombocytosis with an elevated platelet count (higher than 450,000). This study takes place in Salt Lake City, Utah.

Demonstrating the feasibility, effectiveness, and cost-effectiveness of electronically delivered smoking cessation interventions via patient portals in Federally Qualified Health Care (FQHC) settings has the potential for wide-spread dissemination and significant public health impact. on patient populations with demonstrated high rates of smoking.

The purpose of this study is to examine the acute effects of nicotine free electronic cigarette aerosol on vascular function in healthy, non-smokers.

The investigators will study the effect of pulmonary arterial vasodilation to see if it eliminates indices of persistent lung injury in smokers that are susceptible to emphysema.

The purpose of this study is to examine the acute effects of nicotine free electronic cigarette aerosol on vascular function in healthy, non-smokers.

This study will use dual energy x-ray computed tomography (DECT) to evaluate the relationship between heterogeneous perfusion, hypoxia (low oxygen in inspired gas) and induction of pulmonary vascular dilatation to characterize emphysema susceptibility in a normal smoking population.

This study is testing whether a new imaging technique can help healthcare providers diagnose venous thromboembolism. To participate in this study, you must be at least 18 years old and diagnosed with venous thromboembolism. This study takes place in Boston, Massachusetts.